Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer. - Wikidata - awgldk - TriplyDB

Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer.

Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer.

http://www.wikidata.org/entity/Q34695697

about

An integrated approach to the prediction of chemotherapeutic response in patients with breast cancer Pemetrexed as second-line therapy for advanced non-small-cell lung cancer (NSCLC)Perspectives on systems biology applications in diabetic kidney disease Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer Utilization of genomic signatures to identify phenotype-specific drugs Chemotherapy intensity and toxicity among black and white women with advanced and recurrent endometrial cancer: a Gynecologic Oncology Group Study Prospective comparison of clinical and genomic multivariate predictors of response to neoadjuvant chemotherapy in breast cancer.Phase I study of pemetrexed and pegylated liposomal doxorubicin in patients with refractory breast, ovarian, primary peritoneal, or fallopian tube cancer.Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer DNA damage induced by cis- and carboplatin as indicator for in vitro sensitivity of ovarian carcinoma cells.Pharmacological modulation of autophagy enhances Newcastle disease virus-mediated oncolysis in drug-resistant lung cancer cells Emerging role of pemetrexed in ovarian cancer.Robust gene expression signature from formalin-fixed paraffin-embedded samples predicts prognosis of non-small-cell lung cancer patients Practical ethics: establishing a pathway to benefit for complex pharmacogenomic tests.Putting oncology patients at risk ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen.Pharmacogenetics and pharmacogenomics: a bridge to individualized cancer therapy.Non-DNA-binding platinum anticancer agents: Cytotoxic activities of platinum-phosphato complexes towards human ovarian cancer cells Genomic signatures individualize therapeutic decisions in non-small-cell lung cancer.Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer.Characterizing the developmental pathways TTF-1, NKX2-8, and PAX9 in lung cancer.Expression and alternative splicing of folate pathway genes in HapMap lymphoblastoid cell lines Clinical impact of high-throughput gene expression studies in lung cancer.Molecular therapy for the treatment of hepatocellular carcinoma.An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer.Platinum-containing compound platinum pyrithione is stronger and safer than cisplatin in cancer therapy.Independent validation of a model using cell line chemosensitivity to predict response to therapy.Genomic medicine in non-small cell lung cancer: paving the path to personalized care.New biomarkers for lung cancer.DNA repair and cytotoxic drugs: the potential role of RAD51 in clinical outcome of non-small-cell lung cancer patients.Retraction for Harland et al., "Phospholipid bilayers are viscoelastic".Individualizing cancer therapy.Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, IressaR) and chemotherapeutic agents in human lung cancer cells.Statistical Contributions to Bioinformatics: Design, Modeling, Structure Learning, and Integration.Cancer trial errors revealed.A prognostic model for lymph node-negative breast cancer patients based on the integration of proliferation and immunity.Caveats and pitfalls of ROC analysis in clinical microarray research (and how to avoid them)

P2860

Q21144332-E469D753-3174-44D2-B431-CDAAC8CC1CC6 Q24647905-4053C3A5-AE88-4EEA-B3EB-01E011F8A429 Q26823206-8B3F2050-24F6-48A9-9505-9A10BB883D74 Q28396304-90D197E0-99B5-4532-AF78-F847E976C6C0 Q28476014-8323E4FD-723F-42E1-B2BB-9184290EE916 Q30433480-471727D6-D80D-4523-8445-5776C8C43B63 Q30433483-249A077E-7408-4570-B236-6014821936D8 Q33388988-DD62C39D-A8C8-40DB-8030-18C973D4965B Q33463860-3B13DAEB-10E7-454A-B5E7-9A249B728D24 Q33509648-25CEC571-ADAF-4A63-B617-7BB523BDAA3E Q34076586-F99D5A8F-75D0-4478-8BE2-53B0DCD9DD98 Q35015611-83C52910-E539-4D65-8640-A746D6986911 Q35196367-6C430E40-DB95-4B5E-B9ED-AD7B53C2C5AA Q35604133-D282CC22-3B85-4C8B-8F0F-5B8F3325CAE6 Q36327434-F8A96085-931A-4BF6-A8F2-2A058F8C68E8 Q36615632-60738BEC-8AC9-4EF2-A32D-CC718591A23A Q36709301-07EF3C9E-4551-4C3C-9A48-6D36E9B1E51A Q36985163-F587AD41-8301-4149-9C7F-F88B69C84ED1 Q37004642-089B8B9B-9731-46C0-90DD-065976B4C27A Q37040827-99E5CD8C-41E8-4469-8A35-B0FDCB2BF74F Q37146877-19EC974C-AE2E-4807-8503-4EB72E14B079 Q37259813-C3DFCB71-6B13-4C0D-B484-14CADD02CFCC Q37317171-5254F396-8E51-4738-9381-B5515C67F0A1 Q37329048-C938833F-E297-47E8-B6C2-959394B9C585 Q37360211-8928BA74-1D44-4313-9836-7E2C411F11BA Q37619364-5569573A-C239-47D7-908E-7EFC50D1B589 Q37640491-8D3FBA01-6A67-4860-B0B2-835D458579D5 Q37806311-8EEEFA3D-EB59-421E-8FC4-4E62BF5DA24C Q38089079-8D48158F-8DBF-4177-9B71-30E4DAB3ECA2 Q38097536-36D32D4B-8F0A-4099-8B17-E9E64595764A Q42905388-7488BC66-E30B-4CBC-BB5B-DF2CC1890214 Q43005370-9BB9F3C7-E7B8-44CB-B22A-39D225C19286 Q46547397-3345B06C-E55D-4B11-9E99-20B77632D617 Q47110630-67DC04CC-03A5-420D-991F-F37D71992D55 Q48710192-485F32B1-9DF0-4EC5-BAD9-EEF648F65D35 Q53420712-AA1634B8-0D27-4C1D-962E-6DE6DA6D44A2 Q58642712-D29021B4-AEA9-41CF-AF56-06B86440C1F2

P2860

Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer.

http://www.wikidata.org/entity/Q34695697

description

2007 nî lūn-bûn

@nan

2007 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Pharmacogenomic strategies pro ...... patients with advanced cancer.

@ast

Pharmacogenomic strategies pro ...... patients with advanced cancer.

@en

Pharmacogenomic strategies pro ...... patients with advanced cancer.

@nl

type

label

Pharmacogenomic strategies pro ...... patients with advanced cancer.

@ast

Pharmacogenomic strategies pro ...... patients with advanced cancer.

@en

Pharmacogenomic strategies pro ...... patients with advanced cancer.

@nl

prefLabel

Pharmacogenomic strategies pro ...... patients with advanced cancer.

@ast

Pharmacogenomic strategies pro ...... patients with advanced cancer.

@en

Pharmacogenomic strategies pro ...... patients with advanced cancer.

@nl

P1433

Q34695697-D3FFEACC-8EEF-4716-92E0-CDBD0A3C38AC

P1476

Q34695697-5F91755B-C5F8-4B27-A02C-CB7550C1A2B8

P2093

Q34695697-0965A700-E676-488D-8493-D952A7C4FEBA

Q34695697-20DF7D0F-C5B8-4D6E-A95A-EB25F5010E3B

Q34695697-3EE1564E-2B0B-4173-9265-624974C86B5A

Q34695697-570FAD9F-F14D-43FC-8B64-DA348D0979D0

Q34695697-5AA61D9C-4F50-496A-9CD4-FFBB213F0D1E

Q34695697-74808D7A-067C-4E19-8FC5-E0925CE07F57

Q34695697-8CAA2283-090C-4ED8-B340-C58307D92F6D

Q34695697-9EFD2FD7-A8AD-4F7B-86DC-010C4E330B66

Q34695697-B3A49B9C-4069-4B85-82C6-2E26B758BD1E

Q34695697-BCD5F371-8B47-4AB2-8171-C2C40F56134D

P304

Q34695697-8AE33030-B7DB-42EC-B566-3EC5C8E5AF32

P31

Q34695697-093ED51A-ECC4-494A-9356-0B3C4081FE6F

P356

Q34695697-79C3CA6E-ABF6-4E2D-B9C4-6E1B2E9D12DB

P407

Q34695697-50153285-9086-4C8B-84D0-14B9E2CE3D5C

P433

Q34695697-B6C987A6-ABA8-42AF-9D74-B6219013B49A

P478

Q34695697-F38E9B94-E60F-4E84-9762-C65B1D77390E

P577

Q34695697-DF9FA898-7DCF-40DE-A7A1-934DF7429B3E

P698

Q34695697-77F7946A-640B-44D9-981D-470F80267EFD

P921

Q34695697-6788CD6A-21A1-4E35-A34A-63CF585128AF

Q34695697-6BC7262E-708E-409E-8A4D-158BD1A8FC3C

P356

JCO.2007.11.0593

P1433

Journal of Clinical Oncology

P1476

Pharmacogenomic strategies pro ...... patients with advanced cancer.

@en

P2093

Anil Potti

http://www.w3.org/2001/XMLSchema#string

Bala S Balakumaran

http://www.w3.org/2001/XMLSchema#string

Carey Anders

http://www.w3.org/2001/XMLSchema#string

Chaitanya R Acharya

http://www.w3.org/2001/XMLSchema#string

David Harpole

http://www.w3.org/2001/XMLSchema#string

David S Hsu

http://www.w3.org/2001/XMLSchema#string

Holly K Dressman

http://www.w3.org/2001/XMLSchema#string

Johnathan Lancaster

http://www.w3.org/2001/XMLSchema#string

Joseph R Nevins

http://www.w3.org/2001/XMLSchema#string

Katherine Garman

http://www.w3.org/2001/XMLSchema#string

P304

4350-4357

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2007.11.0593

http://www.w3.org/2001/XMLSchema#string

P407

P433

28

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P577

2007-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17906199

http://www.w3.org/2001/XMLSchema#string

P921

pharmacogenomics